The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection.
Saved in:
| Title: | The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection. |
|---|---|
| Authors: | Charles TP; Emory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.; Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America., Burton SL; Emory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.; Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America., Arunachalam PS; Departments of Pathology, and Microbiology and Immunology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, California, United States of America., Cottrell CA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America., Sewall LM; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America., Bollimpelli VS; Emory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.; Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America., Gangadhara S; Emory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.; Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America., Dey AK; International AIDS Vaccine Initiative, New York, New York, United States of America., Ward AB; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America., Shaw GM; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America., Hunter E; Emory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.; Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America., Amara RR; Emory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.; Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.; Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, United States of America., Pulendran B; Departments of Pathology, and Microbiology and Immunology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, California, United States of America., van Gils MJ; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Derdeyn CA; Emory Vaccine Center, Emory University, Atlanta, Georgia, United States of America.; Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America. |
| Source: | PLoS pathogens [PLoS Pathog] 2021 Feb 08; Vol. 17 (2), pp. e1009257. Date of Electronic Publication: 2021 Feb 08 (Print Publication: 2021). |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1553-7374 |
|---|---|
| DOI: | 10.1371/journal.ppat.1009257 |
